146 related articles for article (PubMed ID: 18346205)
1. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.
Gerard M; Debyser Z; Desender L; Baert J; Brandt I; Baekelandt V; Engelborghs Y
J Neurochem; 2008 Jul; 106(1):121-33. PubMed ID: 18346205
[TBL] [Abstract][Full Text] [Related]
2. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
3. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy.
Gerard M; Debyser Z; Desender L; Kahle PJ; Baert J; Baekelandt V; Engelborghs Y
FASEB J; 2006 Mar; 20(3):524-6. PubMed ID: 16410343
[TBL] [Abstract][Full Text] [Related]
4. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells.
Furukawa K; Matsuzaki-Kobayashi M; Hasegawa T; Kikuchi A; Sugeno N; Itoyama Y; Wang Y; Yao PJ; Bushlin I; Takeda A
J Neurochem; 2006 May; 97(4):1071-7. PubMed ID: 16606366
[TBL] [Abstract][Full Text] [Related]
5. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation.
Deleersnijder A; Van Rompuy AS; Desender L; Pottel H; Buée L; Debyser Z; Baekelandt V; Gerard M
J Biol Chem; 2011 Jul; 286(30):26687-701. PubMed ID: 21652707
[TBL] [Abstract][Full Text] [Related]
7. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
8. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
9. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
11. Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties.
Jiang C; Chang JY
Biochemistry; 2007 Jan; 46(2):602-9. PubMed ID: 17209570
[TBL] [Abstract][Full Text] [Related]
12. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
[TBL] [Abstract][Full Text] [Related]
13. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
[TBL] [Abstract][Full Text] [Related]
14. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
15. The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region.
Meuvis J; Gerard M; Desender L; Baekelandt V; Engelborghs Y
Biochemistry; 2010 Nov; 49(43):9345-52. PubMed ID: 20828147
[TBL] [Abstract][Full Text] [Related]
16. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
17. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease.
Hong L; Simon JD
J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659
[TBL] [Abstract][Full Text] [Related]
18. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.
Follmer C; Romão L; Einsiedler CM; Porto TC; Lara FA; Moncores M; Weissmüller G; Lashuel HA; Lansbury P; Neto VM; Silva JL; Foguel D
Biochemistry; 2007 Jan; 46(2):472-82. PubMed ID: 17209557
[TBL] [Abstract][Full Text] [Related]
19. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
20. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
